Skip to content

Mirion Technologies MIR Medical Segment — Goodwill

Other segment segments

Nuclear & Safety
$1.23B+52.2%

Similar metrics at other companies

American Healthcare REIT logo
AHROutpatient Medical — Goodwill
$47.81M0.0%
McKesson logo
MCKMedical-Surgical Solutions — Goodwill
$2.51B0.0%
Novanta logo
NOVTMedical Solutions — Goodwill
$316.9M+14.8%
Voya Financial logo
VOYAInvestment Management Segment — Goodwill
$286M0.0%
Solventum logo
SOLVMedSurg — Goodwill
$4.18B+13.9%
Medtronic logo
MDTReportable Segments — Goodwill
$40.33B+2.2%

Other financials

Income statement

See full
Revenue$257.6M+27.5%
Gross profit$119.1M+23.9%
Operating income$3.7M-57.5%
Net income-$3.4M-1,233%
EPS (diluted)-$0.01

Balance sheet

See full
Cash & equivalents$400.8M+115%
Total debt$478.3M-33.5%
Total equity$1.8B+22.2%
Total assets$3.5B+34.7%

Cash flow

See full
Operating cash flow$18.9M-46.9%
CapEx$9.5M+11.8%
Free cash flow$9.4M-65.3%

Valuation

See full
Market cap$4.55B+35.0%

Profitability

See full
Gross margin47.1%+0.1pp
Operating margin4.7%+0.3pp
Net margin2.6%
FCF margin9.1%-0.6pp

Returns & leverage

See full
Return on equity1.5%
Debt / equity0.3×-0.2×
Current ratio3.2×+1.0×

Where this comes from

Reported directly by Mirion Technologies in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Mirion Technologies’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirion Technologies's medical segment — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirion Technologies's medical segment — goodwill?
Mirion Technologies (MIR) reported medical segment — goodwill of $634M in Q1 2026.
How has Mirion Technologies's medical segment — goodwill changed year-over-year?
Mirion Technologies's medical segment — goodwill decreased by 0.0% year-over-year, from $634M to $634M.
What does medical segment — goodwill mean?
Represents the carrying value of goodwill specifically allocated to the Medical segment following business acquisitions. It reflects the premium paid over the fair value of net identifiable assets, indicating the segment's long-term strategic value and potential for future earnings. Monitoring this balance is essential for assessing impairment risk and the historical success of M&A activities within the medical radiation oncology market.